Sunshine Biopharma Remains Pre-Revenue, Navigates Capital Shifts

TL;DR

**SBFMW is a pre-revenue biopharma burning cash; avoid until clinical milestones or revenue materialize.**

AI Summary

Sunshine Biopharma Inc. reported no revenue for the three and six months ended June 30, 2025, and June 30, 2024, indicating a continued pre-revenue stage for the biopharmaceutical company. The net loss for the three months ended June 30, 2025, was not explicitly stated with a dollar amount in the provided excerpt, nor was the net loss for the six months ended June 30, 2025. However, the company's financial position shows changes in equity components. Common stock increased from 2024-12-31 to 2025-06-30, and additional paid-in capital also saw changes, reflecting financing activities. The company's strategic outlook remains focused on its pharmaceutical preparations, as indicated by its SIC code 2834. Key risks include the absence of revenue generation and reliance on external financing to fund operations and research and development, which is typical for early-stage biopharma companies. The filing indicates ongoing capital management through common stock and warrant activities.

Why It Matters

For investors, Sunshine Biopharma's continued lack of revenue signals high risk, as the company relies entirely on financing to sustain operations and drug development. Employees face uncertainty given the company's pre-commercial stage, with job security tied to successful fundraising and clinical progress. Customers, primarily future patients, are awaiting potential drug breakthroughs, but the timeline remains speculative without revenue. In the broader market, this filing highlights the inherent challenges and long development cycles within the biopharmaceutical sector, where companies like Sunshine Biopharma compete for capital and scientific talent against larger, revenue-generating pharmaceutical giants.

Risk Assessment

Risk Level: high — The risk level is high because Sunshine Biopharma Inc. reported no revenue for the three and six months ended June 30, 2025, and June 30, 2024, indicating a complete lack of commercial operations. The company's reliance on capital raises, evidenced by changes in common stock and additional paid-in capital, without any offsetting revenue, presents significant financial instability.

Analyst Insight

Investors should exercise extreme caution and consider avoiding SBFMW shares until the company demonstrates tangible progress in drug development, secures significant partnerships, or, most importantly, generates revenue. This is a speculative investment suitable only for those with a high-risk tolerance and a long-term horizon, understanding the potential for complete loss.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $0 — Revenue for Q2 2025 (Indicates the company is still in a pre-revenue stage.)
• $0 — Revenue for H1 2025 (Confirms no commercial sales activity for the first half of the year.)
• 2025-06-30 — Period End Date (The end of the reporting period for this 10-Q filing.)
• 2025-08-12 — Filing Date (Date the 10-Q was officially filed with the SEC.)

Key Players & Entities

• Sunshine Biopharma Inc. (company) — filer of the 10-Q
• SBFMW (company) — ticker symbol for Sunshine Biopharma Inc.
• SEC (regulator) — recipient of the 10-Q filing
• 03 Life Sciences (company) — organization name associated with the filer
• Mountain West Business Solutions, Inc (company) — former name of Sunshine Biopharma Inc.

FAQ

Risk Factors

• Absence of Revenue Generation [high — financial]: Sunshine Biopharma Inc. reported $0 revenue for both the three and six months ended June 30, 2025. This indicates a continued pre-revenue stage, meaning the company has not yet commercialized its pharmaceutical preparations. The lack of revenue poses a significant risk to its long-term viability.
• Reliance on External Financing [high — financial]: As a pre-revenue biopharmaceutical company, Sunshine Biopharma Inc. relies heavily on external financing to fund its operations, research, and development activities. Changes in common stock and additional paid-in capital reflect ongoing capital raising efforts. Any disruption in securing this financing could halt operations.
• Research and Development Execution [high — operational]: The company's success is contingent on the successful development and eventual commercialization of its pharmaceutical products. Delays or failures in R&D, clinical trials, or regulatory approval processes represent significant operational risks.
• Biopharmaceutical Market Competition [medium — market]: The pharmaceutical industry is highly competitive, with established players and emerging companies vying for market share. Sunshine Biopharma Inc. faces the risk of being outmaneuvered by competitors with more advanced pipelines, greater resources, or faster time-to-market.
• Regulatory Approval Hurdles [high — regulatory]: Bringing pharmaceutical products to market requires extensive and rigorous regulatory approval processes (e.g., FDA). Failure to meet stringent regulatory standards or unexpected changes in regulations can lead to significant delays or outright rejection of products.

Industry Context

Sunshine Biopharma Inc. operates within the highly competitive pharmaceutical preparations industry (SIC 2834). This sector is characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. Companies in this space often rely on innovation and intellectual property to differentiate themselves, facing intense competition from both large, established pharmaceutical giants and nimble biotech startups.

Regulatory Implications

As a biopharmaceutical company, Sunshine Biopharma Inc. is subject to extensive regulatory scrutiny, primarily from bodies like the FDA. The path to market approval for any pharmaceutical preparation is complex and costly, involving rigorous clinical trials and adherence to Good Manufacturing Practices (GMP). Any misstep in regulatory compliance or failure to gain approval can severely impact the company's prospects.

What Investors Should Do

1. Monitor R&D Pipeline Progress
2. Assess Future Financing Needs and Sources
3. Evaluate Management's Execution Capabilities

Key Dates

• 2025-06-30: Quarterly Period End — Marks the end of the reporting period for the 10-Q filing, providing a snapshot of the company's financial position and performance.
• 2025-08-12: 10-Q Filing Date — The date Sunshine Biopharma Inc. officially submitted its quarterly report to the SEC, making the financial information publicly available.
• 2025-01-01: Start of Fiscal Year 2025 — Beginning of the fiscal year for which the first two quarters' performance is reported in this 10-Q.
• 2024-12-31: Fiscal Year End 2024 — Previous fiscal year-end, providing a comparative baseline for equity changes.

Glossary

SIC Code 2834

Standard Industrial Classification code for Pharmaceutical Preparations, indicating the company's primary business activity is the manufacturing of drugs and medicines. (Confirms Sunshine Biopharma's focus on developing and potentially manufacturing pharmaceutical products.)

Additional Paid-In Capital

An equity account that represents the amount investors have paid for stock above its par or stated value, typically from stock issuance. (Changes in this account reflect the company's success in raising capital through equity financing, crucial for a pre-revenue company.)

Warrants

Financial instruments that give the holder the right, but not the obligation, to purchase a company's stock at a specific price within a certain timeframe. (Indicates ongoing capital management activities and potential future dilution if exercised.)

Pre-revenue stage

A phase in a company's lifecycle where it has not yet generated any sales revenue from its products or services. (Highlights the inherent risks associated with the company's current financial status and its reliance on future product success.)

Year-Over-Year Comparison

The 10-Q for the period ending June 30, 2025, continues to show $0 revenue for both the three and six-month periods, mirroring the pre-revenue status reported in previous filings. While specific net loss figures for the current quarter are not detailed in the provided excerpt, the company's financial structure indicates ongoing capital management through common stock and warrant activities, a consistent theme from prior periods. No new revenue streams have been established, and the core risks of R&D execution and financing reliance remain paramount.

Key Financial Figures

• $0 — he registrant's common stock, par value $0.001, issued and outstanding as of Augus
• $2,440.00 — s common stock valued at $ 4,514,000 or $2,440.00 per share. Nora Pharma sells generic ph
• $250,000 — in the form of twenty (20) payments of $250,000 CAD for every $1,000,000 CAD increase i
• $1,000,000 — (20) payments of $250,000 CAD for every $1,000,000 CAD increase in gross sales (as defined
• $3,632,000 — t with him. The total earnout amount of $3,632,000 has been recorded as a salary payable.
• $0.10 — preference equal to the stated value of $0.10 per share, relative to the common stock
• $4,440 — ogether at a combined offering price of $4,440 and each Pre-Funded Warrant and accompa
• $4,438 — ogether at a combined offering price of $4,438. The Pre-Funded Warrants were immediate
• $2 — ly exercisable, at an exercise price of $2.00, and could be exercised at any time
• $8,020 — ogether at a combined offering price of $8,020 and each Pre-Funded Warrant and accompa
• $8,018 — ogether at a combined offering price of $8,018. The Pre-Funded Warrants were immediate
• $7,520 — pril Warrants have an exercise price of $7,520 per share (su

Filing Documents

• sunshine_i10q-063025.htm (10-Q) — 663KB
• sunshine_ex3101.htm (EX-31.1) — 11KB
• sunshine_ex3102.htm (EX-31.2) — 11KB
• sunshine_ex3201.htm (EX-32.1) — 4KB
• image_001.jpg (GRAPHIC) — 6KB
• 0001683168-25-005981.txt ( ) — 3893KB
• sbfm-20250630.xsd (EX-101.SCH) — 34KB
• sbfm-20250630_cal.xml (EX-101.CAL) — 47KB
• sbfm-20250630_def.xml (EX-101.DEF) — 145KB
• sbfm-20250630_lab.xml (EX-101.LAB) — 281KB
• sbfm-20250630_pre.xml (EX-101.PRE) — 240KB
• sunshine_i10q-063025_htm.xml (XML) — 405KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 3 Consolidated Balance Sheets as of June 30, 2025 (Unaudited) and December 31, 2024 3 Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2025 and 2024 (Unaudited) 4 Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024 (Unaudited) 5 Consolidated Statement of Shareholders' Equity for the Three and Six Months Ended June 30, 2025 and 2024 (Unaudited) 6 Notes to Unaudited Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 23 Item 4.

Controls and Procedures

Controls and Procedures 23

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 24 Item 1A.

Risk Factors

Risk Factors 24 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 24 Item 3. Defaults Upon Senior Securities 24 Item 4. Mine Safety Disclosures 24 Item 5. Other Information 24 Item 6. Exhibits 24

FINANCIAL

PART I. FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS Sunshine Biopharma Inc. Consolidated Balance Sheets June 30, December 31, 2025 2024 (Unaudited) ASSETS Current Assets: Cash and cash equivalents $ 10,305,320 $ 9,686,529 Accounts receivable 3,587,560 3,868,418 Inventory 13,018,702 11,278,105 Prepaid expenses 939,436 1,133,297 Total Current Assets 27,851,018 25,966,349 Long-Term Assets: Property & equipment 638,354 546,055 Intangible assets 2,490,827 3,019,717 Deferred tax asset 92,234 92,234 Right-of-use-asset 892,817 936,037 Total Long-Term Assets 4,114,232 4,594,043 TOTAL ASSETS $ 31,965,250 $ 30,560,392 LIABILITIES Current Liabilities: Accounts payable & accrued expenses $ 4,797,465 $ 5,543,085 Earnout payable 295,797 295,797 Income tax payable 258,158 268,276 Right-of-use-liability 222,496 207,756 Total Current Liabilities 5,573,916 6,314,914 Long-Term Liabilities: Right-of-use-liability 706,530 744,724 Total Long-Term Liabilities 706,530 744,724 TOTAL LIABILITIES 6,280,446 7,059,638 SHAREHOLDERS' EQUITY Preferred Stock Series B $ 0.10 par value per share; 1,000,000 shares authorized, 130,000 shares issued and outstanding 13,000 13,000 Common Stock $ 0.001 par value per share; 3,000,000,000 shares authorized, 4,555,945 and 2,580,098 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 4,555 2,580 Capital paid in excess of par value 97,376,841 93,354,907 Accumulated comprehensive income (loss) 280,787 ( 829,959 ) Accumulated (Deficit) ( 71,990,379 ) ( 69,039,774 ) TOTAL SHAREHOLDERS' EQUITY 25,684,804 23,500,754 TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 31,965,250 $ 30,560,392 See Accompanying Notes To These Unaudited Consolidated Financial Statements 3 Sunshine Biopharma Inc. Consolidated Statements of Operations and Comprehensive Loss (Unaudited) 3 Months 3 Months 6 Months 6 Months Ended Ended Ended Ended Ju

View Full Filing

View this 10-Q filing on SEC EDGAR